IL17A and myocarditis: Semiquantitative evaluation of immunostaining (grades from 0 to 4) for IL-17A and TLR4 showed an increased cardiomyocyte expression of IL-17A in PS myocarditis compared with no-psoriatic patients and vs. controls (respectively, 3.95 ± 0.13 vs. 1.91 ± 0.5 and 3.95 ± 0.13 vs. 0.19 ± 0.2) (Figure 3E).